In 2010 Pfizer purchased King Pharmaceuticals for $3.6 billion or $14.25 a share in cash (a 40 percent premium over King’s closing price the previous day). All three of the drugs (Embeda, Remoxy and Acurox) that made King such a buyout target have proven to be a disaster for Pfizer. How does this correlate to Elite? Well, Elite is going to be producing a better Embeda, in addition to a whole line of ART/ADT opioids. What do you think that does to the value of Elite? The great irony in all of this is ten years ago a friend of mine told me about ELI. Guess where he worked at the time? Pfizer.